



Pfizer Inc.  
66 Hudson Blvd E  
New York, NY 10001

August 15, 2026

**Subject: Pfizer will discontinue distribution of Norpace® CR 150 mg and Norpace® CR 100 mg**

Dear Healthcare Provider,

The purpose of this letter is to inform you that Pfizer has made the decision to permanently discontinue distribution of Norpace CR (disopyramide phosphate extended-release) 100 mg and 150 mg capsules in the United States due to ongoing manufacturing challenges. This decision is not related to any safety, efficacy, or quality concerns associated with Norpace CR.

Norpace IR (disopyramide phosphate immediate release) 100 mg and 150 mg capsules remain available and are not impacted by this discontinuation.

Healthcare professionals should use their clinical judgement to determine alternative treatment options for affected patients.

For medical questions on Norpace CR, please contact Pfizer Medical Information 1-800-438-1985. The full Prescribing Information for Norpace and Norpace CR can be found at: [NORPACE® and NORPACE® CR | Pfizer](#).

Healthcare providers are encouraged to report adverse events, including product defects, by contacting Pfizer at 1-800-438-1985 or by contacting the FDA at <http://www.fda.gov/Safety/MedWatch> or by calling 1-800-FDA-1088.

Sincerely,

A handwritten signature in black ink that reads 'Jorie Frasiolas'.

Jorie Frasiolas, PharmD, BCPS  
U.S. Medical Affairs Pfizer Inc.